Summary:
- The U.S. Food and Drug Administration (FDA) has approved the drug BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma.
- Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow, and can lead to various complications such as bone damage, kidney problems, and weakened immune system.
- BLENREP is a novel antibody-drug conjugate that targets a specific protein on the surface of myeloma cells, delivering a potent anti-cancer drug to kill the cancer cells while minimizing harm to healthy cells.